Skip To Main Content
Júlia Maria Olivieri on Muck Rack

Júlia Maria Olivieri

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Júlia Maria

Contact Júlia Maria, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Analysis of the coding transcriptome in NSCLC highlights variant-specific gene expression and signaling in CD74-ROS1 fusions

|
By Jasmine Vargas, Julia Eve Olivieri, Júlia Maria Olivieri, Georgios Pantouris
| Nature Verified
Abstract The CD74-ROS1 fusion protein is an aggressive oncogenic driver detected in non-small cell lung cancer (NSCLC) patients from stages I-IV. Despite its rare occurrence, CD74-ROS1 has a notable clinical value, with ROS1 inhibitors used as first-line therapeutics in precision medicine. Upon targeting the cancer with ROS1 tyrosine kinase inhibitors (TKIs), resistance occasionally emerges for reasons that are not well-understood.
Open in Who Shared Issue with article?

Analysis of the Coding Transcriptome in NSCLC Highlights Variant-Specific Gene Expression and Signaling in CD74-ROS1 Fusions

|
By Jasmine Vargas, Julia Eve Olivieri, Júlia Maria Olivieri, Georgios Pantouris
| preprints.org
This version is not peer-reviewed. Jasmine Vargas,Julia Olivieri  *,Georgios Pantouris  * Jasmine Vargas,Julia Olivieri  *,Georgios Pantouris  * Submitted: 05 November 2025 You are already at the latest version The CD74-ROS1 fusion protein is an aggressive oncogenic driver detected in non-small cell lung cancer (NSCLC) patients from stages I-IV. Despite the low occurrence, CD74-ROS1 has a notable clinical value serving as a therapeutic target when the primary treatment plan fails.
Open in Who Shared Issue with article?
See all 2 articles